It is plausible to surmise that a better understanding of the expression of SARS-CoV-2 receptors is highly warranted in lung cancer patients, particularly in LUADs, whose pathogenesis is linked to ACE2-expressing airway lineages (e.g., AT2), and also since LUADs arise in the lung periphery, a major site for the development of pneumonia in COVID-19 patients. This evidence concerns the gene ACE2 and COVID-19.